ASD and the gut microbiota: Emerging insights into autism treatment

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social communication, social interaction, and restrictive, repetitive behaviors. Changes in diagnostic criteria and better awareness have led to a higher prevalence of autism. ASD has a heterogenous etiology with genetics and environmental factors playing major roles. GI symptoms like constipation, diarrhea and abdominal discomfort are prevalent in children with ASD and affect up to 70% of patients. Recent research has drawn attention to gut dysbiosis which has been linked to gastrointestinal and neurodevelopmental symptoms. Increased intestinal permeability and microbial metabolite differences have also been implicated in the pathophysiology of ASD, with certain microbial species, like Clostridia playing a major role. Probiotics, ketogenic diets and fecal microbiota transplantation are all therapeutic interventions that have shown potential in reducing ASD symptoms. However, more research is needed to establish the safety and long-term efficacy of these interventions. This paper explores the relationship between gut microbiota and ASD and its potential as a therapeutic target. Further studies such as using a multi-omics approach would be beneficial to better understand the interactions of gut microbes and ASD, possibly allowing for novel therapeutic interventions.